Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exelon for Dementia in Progressive Supranuclear Palsy
NCT00522015Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Feb 2008
- Primary completion
- Dec 2009
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of rivastigmine in progressive supranuclear palsy (PSP) and Dementia, sponsored by University Hospital Tübingen. Primary endpoint: Neuropsychological assessments for memory and executive function at 6 months. Status: unknown.
02
Drugs
rivastigmine
03
Conditions
progressive supranuclear palsy (PSP)Dementia
Beyond the preview
Go deeper on NCT00522015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522015.